A digital protein microarray for COVID-19 cytokine storm monitoring.
A digital protein microarray for COVID-19 cytokine storm monitoring.
复制标题
用于COVID-19细胞因子暴风雨监测的数字蛋白微阵列。
DOI：
10.1039/d0lc00678e
复制
发表时间：
2021-01-21
期刊：
影响因子：
6.1
通讯作者：
Kurabayashi K
中科院分区：
文献类型：
--
作者：
Song Y;Ye Y;Su SH;Stephens A;Cai T;Chung MT;Han MK;Newstead MW;Yessayan L;Frame D;Humes HD;Singer BH;Kurabayashi K
尽管人们普遍担心细胞因子风暴会导致COVID-19的严重发病率，但快速细胞因子测定法并不能常规用于监测重症患者。我们报告了一种数字蛋白质微阵列平台的临床应用，该平台用于对密歇根大学医院重症监护室（ICU）收治的重症COVID-19患者的细胞因子进行快速多重定量。该平台包括两个低成本模块：（i）半自动流体分配/混合模块，可在生物安全柜内操作，以最大限度地减少技术人员暴露于病毒感染，以及（ii）12-12-15英寸紧凑型荧光光学扫描仪，用于潜在的床边读数。该平台能够在临床实践中进行日常细胞因子分析，具有高灵敏度（<0.4pg/mL），检测间重复性（约10%CV）和快速操作，可在4小时内提供治疗进展的反馈。该试验使我们能够对两名呼吸衰竭危重患者进行连续监测，并支持使用选择性细胞移植装置（SCD）进行免疫调节治疗。我们还观察到接受托珠单抗（IL-6抑制剂）后白细胞介素-6（IL-6）明显升高，而所有重症COVID-19患者中存在显著的细胞因子谱变异性，并发现IL-6与临床生物标志物（如铁蛋白和C-反应蛋白（CRP））之间的弱相关性。我们的数据显示，患者对COVID-19的反应存在很大的受试者间差异，这再次证实了需要通过快速细胞因子检测指导个性化策略。数字微流控免疫分析平台能够快速多重定量重症COVID-19患者血清中的促炎细胞因子。
Despite widespread concern for cytokine storms leading to severe morbidity in COVID-19, rapid cytokine assays are not routinely available for monitoring critically ill patients. We report the clinical application of a digital protein microarray platform for rapid multiplex quantification of cytokines from critically ill COVID-19 patients admitted to the intensive care unit (ICU) at the University of Michigan Hospital. The platform comprises two low-cost modules: (i) a semi-automated fluidic dispensing/mixing module that can be operated inside a biosafety cabinet to minimize the exposure of technician to the virus infection and (ii) a 12-12-15 inch compact fluorescence optical scanner for the potential near-bedside readout. The platform enabled daily cytokine analysis in clinical practice with high sensitivity (<0.4pg/mL), inter-assay repeatability (~10% CV), and rapid operation providing feedback on the progress of therapy within 4 hours. This test allowed us to perform serial monitoring of two critically ill patients with respiratory failure and to support the immunomodulatory therapy using the selective cytopheretic device (SCD). We also observed clear interleukin-6 (IL-6) elevations after receiving tocilizumab (IL-6 inhibitor) while significant cytokine profile variability exists across all critically ill COVID-19 patients and to discover a weak correlation between IL-6 to clinical biomarkers, such as ferritin and c-reactive protein (CRP). Our data revealed large subject-to-subject variability in patients’ response to COVID-19, reaffirming the need for a personalized strategy guided by rapid cytokine assays. A digital microfluidic immunoassay platform enables rapid multiplex quantification of proinflammatory cytokines in serum for critically ill COVID-19 patients.
登录
查看更多内容
影响因子：
17.1
作者：
Min J;Nothing M;Coble B;Zheng H;Park J;Im H;Weber GF;Castro CM;Swirski FK;Weissleder R;Lee H
通讯作者：
Lee H
可编程生物 - 纳米芯平台：具有学习能力的即时生物传感器系统。
影响因子：
18.3
作者：
McRae MP;Simmons G;Wong J;McDevitt JT
通讯作者：
McDevitt JT
DOI：
10.1038/nrclinonc.2017.148
发表时间：
2018-01
期刊：
Nature reviews. Clinical oncology
影响因子：
--
作者：
Neelapu SS;Tummala S;Kebriaei P;Wierda W;Gutierrez C;Locke FL;Komanduri KV;Lin Y;Jain N;Daver N;Westin J;Gulbis AM;Loghin ME;de Groot JF;Adkins S;Davis SE;Rezvani K;Hwu P;Shpall EJ
通讯作者：
Shpall EJ
影响因子：
3.1
作者：
de Brito RC;Lucena-Silva N;Torres LC;Luna CF;Correia JB;da Silva GA
通讯作者：
da Silva GA
影响因子：
28.3
作者：
Gorbalenya, Alexander E.;Baker, Susan C.;Ziebuhr, John
通讯作者：
Ziebuhr, John